KEY HIGHLIGHTS

• Neuranics Lab's MorphX uses lab-on-cartridge technology for rapid blood tests.
• The platform employs multi-spectral imaging and deep learning for accurate diagnostics.
• Despite varied funding reports, the company has secured investments from notable entities.
• MorphX aims to provide timely results, crucial in emergency and remote healthcare settings.

Introduction

In 2026, Neuranics Lab continues to make strides in the field of point-of-care diagnostics with its innovative platform, MorphX. This technology promises to transform how blood count tests are conducted, especially in regions where traditional methods are impractical.

Company Overview

Neuranics Lab was incorporated on March 25, 2021, in New Delhi. Founded by Ashutosh Patra and Praveen Kumar, the company focuses on developing affordable and accessible diagnostic solutions. With a team size ranging from 17 to 21 employees, Neuranics Lab operates within the point-of-care diagnostics sector.

Technology Behind MorphX

MorphX represents a significant leap in point-of-care diagnostics. The platform utilizes a lab-on-cartridge technology, where a microfluidic cartridge handles sample preparation steps traditionally done by hand in a laboratory.

MorphX employs multi-spectral imaging combined with deep learning to analyze blood samples. Unlike conventional analyzers that use electrical methods to count cells, MorphX photographs cells across several wavelengths and interprets the images. This approach covers over 20 parameters, including morphology, which involves examining the shapes and appearances of cells.

The technology claims to handle complex tasks such as low platelet counts, differential counts, malaria parasites, nucleated red blood cells, and atypical cells. These capabilities are crucial for early and accurate diagnosis, especially in remote and underserved areas.

Clinical Trials and Validation

A clinical trial comparing MorphX against an existing imported analyzer has been registered on India's Clinical Trials Registry. However, as of the latest available records, it is listed as not yet recruiting, and no results have been published.

Funding and Investors

Neuranics Lab's funding details are somewhat unclear, with databases providing varying totals ranging from $700,000 to $1.48 million across up to four rounds. The most corroborated event is a $700,000 seed round led by Inflection Point Ventures in December 2024, aimed at technology development and clinical validation.

The company's investors include Inflection Point Ventures, the UK-India fund Pontaq, Venture Center in Pune, the Atal Incubation Centre at CCMB in Hyderabad, and an HDFC Parivartan grant. These investments highlight the potential and promise of MorphX in revolutionizing point-of-care diagnostics.

Market Potential and Future Prospects

The market potential for MorphX is significant, given the widespread need for rapid and accurate diagnostic tools in primary health centers and small clinics, especially in rural and underserved areas of India. The ability to provide results in minutes rather than hours can drastically improve patient outcomes, particularly in emergency situations.

While regulatory clearance and commercial deployment have yet to be announced, the ongoing development and the backing from reputable investors suggest a promising future for Neuranics Lab and its MorphX platform.

FAQ Section

**Q: What is MorphX by Neuranics Lab? **A: MorphX is an innovative point-of-care diagnostics platform developed by Neuranics Lab. It uses lab-on-cartridge technology to provide rapid and accurate blood count tests without the need for skilled technicians.

**Q: How does MorphX work? **A: MorphX uses multi-spectral imaging and deep learning to analyze blood samples. It photographs cells across several wavelengths and interprets the images to cover over 20 parameters, including morphology.

**Q: What are the key benefits of MorphX? **A: The key benefits include rapid results in minutes, the ability to handle complex diagnostic tasks, and the potential to improve healthcare delivery in remote and underserved areas.

Conclusion

Neuranics Lab's MorphX holds the promise of transforming point-of-care diagnostics in India. With its innovative technology and strong investor backing, MorphX is poised to make a significant impact on healthcare delivery, especially in regions where traditional diagnostic methods fall short.

Call-to-Action

For more information on Neuranics Lab and its groundbreaking technology, visit blogy.in.